Does the media refer more to TNGX or CGEM?

In the previous week, Cullinan Therapeutics had 1 more articles in the media than Tango Therapeutics. MarketBeat recorded 3 mentions for Cullinan Therapeutics and 2 mentions for Tango Therapeutics. Tango Therapeutics' average media sentiment score of 0.93 beat Cullinan Therapeutics' score of 0.60 indicating that Tango Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tango Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cullinan Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings and valuation, CGEM or EWTX?

Edgewise Therapeutics is trading at a lower price-to-earnings ratio than Cullinan Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cullinan Therapeutics N/A N/A -$219.88M -$3.36 N/A Edgewise Therapeutics N/A N/A -$167.79M -$1.66 N/A

Is CGEM or EWTX more profitable?

Edgewise Therapeutics' return on equity of -32.55% beat Cullinan Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Cullinan Therapeutics N/A -51.45% -47.64% Edgewise Therapeutics N/A -32.55% -31.04%

Does the media favor CGEM or EWTX?

In the previous week, Cullinan Therapeutics had 1 more articles in the media than Edgewise Therapeutics. MarketBeat recorded 3 mentions for Cullinan Therapeutics and 2 mentions for Edgewise Therapeutics. Edgewise Therapeutics' average media sentiment score of 1.50 beat Cullinan Therapeutics' score of 0.60 indicating that Edgewise Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cullinan Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Edgewise Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Which has preferable valuation and earnings, VKTX or CGEM?

Viking Therapeutics is trading at a lower price-to-earnings ratio than Cullinan Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Viking Therapeutics N/A N/A -$359.64M -$4.14 N/A Cullinan Therapeutics N/A N/A -$219.88M -$3.36 N/A

Is VKTX or CGEM more profitable?

Cullinan Therapeutics' return on equity of -51.45% beat Viking Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Viking Therapeutics N/A -71.31% -65.35% Cullinan Therapeutics N/A -51.45% -47.64%

Does the media refer more to VKTX or CGEM?

In the previous week, Viking Therapeutics had 11 more articles in the media than Cullinan Therapeutics. MarketBeat recorded 14 mentions for Viking Therapeutics and 3 mentions for Cullinan Therapeutics. Cullinan Therapeutics' average media sentiment score of 0.60 beat Viking Therapeutics' score of 0.55 indicating that Cullinan Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Viking Therapeutics 4 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Cullinan Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings and valuation, DNLI or CGEM?

Denali Therapeutics is trading at a lower price-to-earnings ratio than Cullinan Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Denali Therapeutics N/A N/A -$512.54M -$2.88 N/A Cullinan Therapeutics N/A N/A -$219.88M -$3.36 N/A

Is DNLI or CGEM more profitable?

Cullinan Therapeutics' return on equity of -51.45% beat Denali Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Denali Therapeutics N/A -52.20% -43.86% Cullinan Therapeutics N/A -51.45% -47.64%

Does the media refer more to DNLI or CGEM?

In the previous week, Cullinan Therapeutics had 1 more articles in the media than Denali Therapeutics. MarketBeat recorded 3 mentions for Cullinan Therapeutics and 2 mentions for Denali Therapeutics. Denali Therapeutics' average media sentiment score of 0.94 beat Cullinan Therapeutics' score of 0.60 indicating that Denali Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Denali Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cullinan Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer ACAD or CGEM?

In the previous week, ACADIA Pharmaceuticals had 8 more articles in the media than Cullinan Therapeutics. MarketBeat recorded 11 mentions for ACADIA Pharmaceuticals and 3 mentions for Cullinan Therapeutics. ACADIA Pharmaceuticals' average media sentiment score of 0.93 beat Cullinan Therapeutics' score of 0.60 indicating that ACADIA Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ACADIA Pharmaceuticals 6 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Cullinan Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Cullinan Therapeutics (CGEM) Competitors

$18.40 0.00 (0.00%)

Closing price 06/26/2026 04:00 PM Eastern

Extended Trading

$18.50 +0.10 (+0.55%)

As of 05:35 AM Eastern

Compare

CGEM vs. TNGX, EWTX, VKTX, DNLI, and ACAD

Should you buy Cullinan Therapeutics stock or one of its competitors? MarketBeat compares Cullinan Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Cullinan Therapeutics include Tango Therapeutics (TNGX), Edgewise Therapeutics (EWTX), Viking Therapeutics (VKTX), Denali Therapeutics (DNLI), and ACADIA Pharmaceuticals (ACAD). These companies are all part of the "pharmaceutical products" industry.

How does Cullinan Therapeutics compare to Tango Therapeutics?

Tango Therapeutics (NASDAQ:TNGX) and Cullinan Therapeutics (NASDAQ:CGEM) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, risk, dividends, earnings, media sentiment, analyst recommendations, institutional ownership and profitability.

In the previous week, Cullinan Therapeutics had 1 more articles in the media than Tango Therapeutics. MarketBeat recorded 3 mentions for Cullinan Therapeutics and 2 mentions for Tango Therapeutics. Tango Therapeutics' average media sentiment score of 0.93 beat Cullinan Therapeutics' score of 0.60 indicating that Tango Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tango Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cullinan Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Tango Therapeutics currently has a consensus target price of $41.17, suggesting a potential upside of 30.81%. Cullinan Therapeutics has a consensus target price of $32.00, suggesting a potential upside of 73.91%. Given Cullinan Therapeutics' higher possible upside, analysts plainly believe Cullinan Therapeutics is more favorable than Tango Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tango Therapeutics	1 Sell rating(s)	2 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.73
Cullinan Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

Tango Therapeutics has higher revenue and earnings than Cullinan Therapeutics. Tango Therapeutics is trading at a lower price-to-earnings ratio than Cullinan Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tango Therapeutics	$62.38M	72.97	-$101.59M	-$0.83	N/A
Cullinan Therapeutics	N/A	N/A	-$219.88M	-$3.36	N/A

79.0% of Tango Therapeutics shares are held by institutional investors. Comparatively, 86.3% of Cullinan Therapeutics shares are held by institutional investors. 6.5% of Tango Therapeutics shares are held by insiders. Comparatively, 8.6% of Cullinan Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Cullinan Therapeutics has a net margin of 0.00% compared to Tango Therapeutics' net margin of -151.15%. Tango Therapeutics' return on equity of -41.54% beat Cullinan Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tango Therapeutics	-151.15%	-41.54%	-33.44%
Cullinan Therapeutics	N/A	-51.45%	-47.64%

Tango Therapeutics has a beta of 1.19, suggesting that its stock price is 19% more volatile than the broader market. Comparatively, Cullinan Therapeutics has a beta of -0.01, suggesting that its stock price is 101% less volatile than the broader market.

Summary

Tango Therapeutics beats Cullinan Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Cullinan Therapeutics compare to Edgewise Therapeutics?

Cullinan Therapeutics (NASDAQ:CGEM) and Edgewise Therapeutics (NASDAQ:EWTX) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, dividends, risk, institutional ownership, earnings, media sentiment, analyst recommendations and profitability.

86.3% of Cullinan Therapeutics shares are held by institutional investors. 8.6% of Cullinan Therapeutics shares are held by insiders. Comparatively, 21.3% of Edgewise Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Edgewise Therapeutics' return on equity of -32.55% beat Cullinan Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cullinan Therapeutics	N/A	-51.45%	-47.64%
Edgewise Therapeutics	N/A	-32.55%	-31.04%

Cullinan Therapeutics has a beta of -0.01, indicating that its share price is 101% less volatile than the broader market. Comparatively, Edgewise Therapeutics has a beta of 0.27, indicating that its share price is 73% less volatile than the broader market.

In the previous week, Cullinan Therapeutics had 1 more articles in the media than Edgewise Therapeutics. MarketBeat recorded 3 mentions for Cullinan Therapeutics and 2 mentions for Edgewise Therapeutics. Edgewise Therapeutics' average media sentiment score of 1.50 beat Cullinan Therapeutics' score of 0.60 indicating that Edgewise Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cullinan Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Edgewise Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Edgewise Therapeutics is trading at a lower price-to-earnings ratio than Cullinan Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cullinan Therapeutics	N/A	N/A	-$219.88M	-$3.36	N/A
Edgewise Therapeutics	N/A	N/A	-$167.79M	-$1.66	N/A

Cullinan Therapeutics currently has a consensus price target of $32.00, suggesting a potential upside of 73.91%. Edgewise Therapeutics has a consensus price target of $47.30, suggesting a potential upside of 14.09%. Given Cullinan Therapeutics' higher probable upside, equities research analysts plainly believe Cullinan Therapeutics is more favorable than Edgewise Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cullinan Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Edgewise Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78

Summary

Edgewise Therapeutics beats Cullinan Therapeutics on 9 of the 13 factors compared between the two stocks.

How does Cullinan Therapeutics compare to Viking Therapeutics?

Viking Therapeutics (NASDAQ:VKTX) and Cullinan Therapeutics (NASDAQ:CGEM) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, media sentiment, earnings, institutional ownership, risk, profitability and valuation.

Viking Therapeutics presently has a consensus price target of $93.60, indicating a potential upside of 146.06%. Cullinan Therapeutics has a consensus price target of $32.00, indicating a potential upside of 73.91%. Given Viking Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Viking Therapeutics is more favorable than Cullinan Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Viking Therapeutics	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	2.79
Cullinan Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

Viking Therapeutics is trading at a lower price-to-earnings ratio than Cullinan Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Viking Therapeutics	N/A	N/A	-$359.64M	-$4.14	N/A
Cullinan Therapeutics	N/A	N/A	-$219.88M	-$3.36	N/A

Cullinan Therapeutics' return on equity of -51.45% beat Viking Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Viking Therapeutics	N/A	-71.31%	-65.35%
Cullinan Therapeutics	N/A	-51.45%	-47.64%

Viking Therapeutics has a beta of 0.69, indicating that its share price is 31% less volatile than the broader market. Comparatively, Cullinan Therapeutics has a beta of -0.01, indicating that its share price is 101% less volatile than the broader market.

76.0% of Viking Therapeutics shares are owned by institutional investors. Comparatively, 86.3% of Cullinan Therapeutics shares are owned by institutional investors. 5.3% of Viking Therapeutics shares are owned by company insiders. Comparatively, 8.6% of Cullinan Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, Viking Therapeutics had 11 more articles in the media than Cullinan Therapeutics. MarketBeat recorded 14 mentions for Viking Therapeutics and 3 mentions for Cullinan Therapeutics. Cullinan Therapeutics' average media sentiment score of 0.60 beat Viking Therapeutics' score of 0.55 indicating that Cullinan Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Viking Therapeutics	4 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
Cullinan Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Cullinan Therapeutics beats Viking Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Cullinan Therapeutics compare to Denali Therapeutics?

Denali Therapeutics (NASDAQ:DNLI) and Cullinan Therapeutics (NASDAQ:CGEM) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, dividends, risk, media sentiment, institutional ownership, earnings, profitability and analyst recommendations.

92.9% of Denali Therapeutics shares are held by institutional investors. Comparatively, 86.3% of Cullinan Therapeutics shares are held by institutional investors. 12.5% of Denali Therapeutics shares are held by insiders. Comparatively, 8.6% of Cullinan Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Cullinan Therapeutics' return on equity of -51.45% beat Denali Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Denali Therapeutics	N/A	-52.20%	-43.86%
Cullinan Therapeutics	N/A	-51.45%	-47.64%

In the previous week, Cullinan Therapeutics had 1 more articles in the media than Denali Therapeutics. MarketBeat recorded 3 mentions for Cullinan Therapeutics and 2 mentions for Denali Therapeutics. Denali Therapeutics' average media sentiment score of 0.94 beat Cullinan Therapeutics' score of 0.60 indicating that Denali Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Denali Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cullinan Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Denali Therapeutics has a beta of 1.03, suggesting that its stock price is 3% more volatile than the broader market. Comparatively, Cullinan Therapeutics has a beta of -0.01, suggesting that its stock price is 101% less volatile than the broader market.

Denali Therapeutics is trading at a lower price-to-earnings ratio than Cullinan Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Denali Therapeutics	N/A	N/A	-$512.54M	-$2.88	N/A
Cullinan Therapeutics	N/A	N/A	-$219.88M	-$3.36	N/A

Denali Therapeutics currently has a consensus target price of $34.25, suggesting a potential upside of 33.95%. Cullinan Therapeutics has a consensus target price of $32.00, suggesting a potential upside of 73.91%. Given Cullinan Therapeutics' higher probable upside, analysts plainly believe Cullinan Therapeutics is more favorable than Denali Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Denali Therapeutics	1 Sell rating(s)	2 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.81
Cullinan Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

Summary

Denali Therapeutics beats Cullinan Therapeutics on 9 of the 14 factors compared between the two stocks.

How does Cullinan Therapeutics compare to ACADIA Pharmaceuticals?

ACADIA Pharmaceuticals (NASDAQ:ACAD) and Cullinan Therapeutics (NASDAQ:CGEM) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, earnings, dividends, risk, institutional ownership, profitability and valuation.

In the previous week, ACADIA Pharmaceuticals had 8 more articles in the media than Cullinan Therapeutics. MarketBeat recorded 11 mentions for ACADIA Pharmaceuticals and 3 mentions for Cullinan Therapeutics. ACADIA Pharmaceuticals' average media sentiment score of 0.93 beat Cullinan Therapeutics' score of 0.60 indicating that ACADIA Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ACADIA Pharmaceuticals	6 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Cullinan Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

96.7% of ACADIA Pharmaceuticals shares are owned by institutional investors. Comparatively, 86.3% of Cullinan Therapeutics shares are owned by institutional investors. 26.2% of ACADIA Pharmaceuticals shares are owned by insiders. Comparatively, 8.6% of Cullinan Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

ACADIA Pharmaceuticals has a beta of 0.84, indicating that its stock price is 16% less volatile than the broader market. Comparatively, Cullinan Therapeutics has a beta of -0.01, indicating that its stock price is 101% less volatile than the broader market.

ACADIA Pharmaceuticals has higher revenue and earnings than Cullinan Therapeutics. Cullinan Therapeutics is trading at a lower price-to-earnings ratio than ACADIA Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ACADIA Pharmaceuticals	$1.10B	3.96	$391M	$2.20	11.51
Cullinan Therapeutics	N/A	N/A	-$219.88M	-$3.36	N/A

ACADIA Pharmaceuticals has a net margin of 34.30% compared to Cullinan Therapeutics' net margin of 0.00%. ACADIA Pharmaceuticals' return on equity of 9.61% beat Cullinan Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ACADIA Pharmaceuticals	34.30%	9.61%	7.07%
Cullinan Therapeutics	N/A	-51.45%	-47.64%

ACADIA Pharmaceuticals presently has a consensus price target of $31.63, indicating a potential upside of 24.90%. Cullinan Therapeutics has a consensus price target of $32.00, indicating a potential upside of 73.91%. Given Cullinan Therapeutics' higher probable upside, analysts plainly believe Cullinan Therapeutics is more favorable than ACADIA Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ACADIA Pharmaceuticals	1 Sell rating(s)	3 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.67
Cullinan Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

Summary

ACADIA Pharmaceuticals beats Cullinan Therapeutics on 14 of the 15 factors compared between the two stocks.

Get Cullinan Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CGEM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CGEM vs. The Competition

Export

Metric	Cullinan Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.13B	$3.62B	$6.83B	$12.17B
Dividend Yield	N/A	2.21%	2.66%	6.11%
P/E Ratio	-5.48	21.75	25.91	24.17
Price / Sales	N/A	340.46	548.81	101.11
Price / Cash	N/A	62.10	29.09	36.93
Price / Book	2.66	8.31	10.82	6.38
Net Income	-$219.88M	$23.92M	$3.58B	$337.00M
7 Day Performance	6.36%	1.93%	1.90%	-0.23%
1 Month Performance	11.92%	-0.41%	-0.26%	-1.40%
1 Year Performance	137.11%	65.22%	34.40%	27.76%

Cullinan Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CGEM Cullinan Therapeutics	2.6857 of 5 stars	$18.40 flat	$32.00 +73.9%	+137.1%	$1.13B	N/A	N/A	30
TNGX Tango Therapeutics	2.7736 of 5 stars	$29.03 +1.9%	$38.42 +32.3%	+528.1%	$4.20B	$62.38M	N/A	90
EWTX Edgewise Therapeutics	3.4948 of 5 stars	$38.18 +4.6%	$47.30 +23.9%	+214.8%	$4.11B	N/A	N/A	60	Positive News
VKTX Viking Therapeutics	2.7547 of 5 stars	$34.29 +5.9%	$93.60 +173.0%	+43.4%	$3.98B	N/A	N/A	20
DNLI Denali Therapeutics	3.0702 of 5 stars	$24.90 +3.5%	$34.25 +37.6%	+81.3%	$3.95B	N/A	N/A	430	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CGEM) was last updated on 6/29/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cullinan Therapeutics (CGEM) Competitors

CGEM vs. TNGX, EWTX, VKTX, DNLI, and ACAD

How does Cullinan Therapeutics compare to Tango Therapeutics?

Summary

How does Cullinan Therapeutics compare to Edgewise Therapeutics?

Summary

How does Cullinan Therapeutics compare to Viking Therapeutics?

Summary

How does Cullinan Therapeutics compare to Denali Therapeutics?

Summary

How does Cullinan Therapeutics compare to ACADIA Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CGEM vs. The Competition

Cullinan Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Cullinan Therapeutics (CGEM) Competitors

CGEM vs. TNGX, EWTX, VKTX, DNLI, and ACAD

How does Cullinan Therapeutics compare to Tango Therapeutics?

Does the media refer more to TNGX or CGEM?

Do analysts recommend TNGX or CGEM?

Which has preferable earnings and valuation, TNGX or CGEM?

Do insiders and institutionals hold more shares of TNGX or CGEM?

Is TNGX or CGEM more profitable?

Which has more volatility & risk, TNGX or CGEM?

Summary

How does Cullinan Therapeutics compare to Edgewise Therapeutics?

Do insiders and institutionals hold more shares of CGEM or EWTX?

Is CGEM or EWTX more profitable?

Which has more volatility & risk, CGEM or EWTX?

Does the media favor CGEM or EWTX?

Which has stronger earnings and valuation, CGEM or EWTX?

Do analysts recommend CGEM or EWTX?

Summary

How does Cullinan Therapeutics compare to Viking Therapeutics?

Do analysts rate VKTX or CGEM?

Which has preferable valuation and earnings, VKTX or CGEM?

Is VKTX or CGEM more profitable?

Which has more volatility & risk, VKTX or CGEM?

Do institutionals and insiders believe in VKTX or CGEM?

Does the media refer more to VKTX or CGEM?

Summary

How does Cullinan Therapeutics compare to Denali Therapeutics?

Do institutionals & insiders believe in DNLI or CGEM?

Is DNLI or CGEM more profitable?

Does the media refer more to DNLI or CGEM?

Which has more volatility & risk, DNLI or CGEM?

Which has stronger earnings and valuation, DNLI or CGEM?

Do analysts prefer DNLI or CGEM?

Summary

How does Cullinan Therapeutics compare to ACADIA Pharmaceuticals?

Does the media prefer ACAD or CGEM?

Do insiders & institutionals believe in ACAD or CGEM?

Which has more risk & volatility, ACAD or CGEM?

Which has higher valuation & earnings, ACAD or CGEM?

Is ACAD or CGEM more profitable?

Do analysts rate ACAD or CGEM?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CGEM vs. The Competition

Cullinan Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools